Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$900M |
| 2 |
Cisco
CSCO
|
+$204M |
| 3 |
Amazon
AMZN
|
+$152M |
| 4 |
Johnson & Johnson
JNJ
|
+$150M |
| 5 |
Brookfield Infrastructure
BIPC
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$430M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$305M |
| 3 |
TWNK
Hostess Brands, Inc. Class A Common Stock
TWNK
|
+$299M |
| 4 |
Merck
MRK
|
+$291M |
| 5 |
TRTN
Triton International Limited
TRTN
|
+$282M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.11% |
| 2 | Financials | 17.15% |
| 3 | Industrials | 13.2% |
| 4 | Consumer Discretionary | 11.26% |
| 5 | Healthcare | 10.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3126
Black Diamond Therapeutics
BDTX
$98.6M
| $312K | ﹤0.01% |
110,612
+58,354
| +112% | +$137K |
|
3127
Nektar Therapeutics
NKTR
$2.41B
| $309K | ﹤0.01% |
36,444
-2,755
| -7% | -$20.9K |
|
3128
Solid Biosciences
SLDB
$836M
| $307K | ﹤0.01% |
49,950
-5,140
| -9% | -$16.4K |
|
3129
HireQuest
HQI
$188M
| $307K | ﹤0.01% |
19,977
| – | – |
|
3130
Relmada Therapeutics
RLMD
$562M
| $305K | ﹤0.01% |
73,820
| – | – |
|
3131
Praxis Precision Medicines
PRAX
$8.58B
| $305K | ﹤0.01% |
13,710
+12,302
| +874% | +$222K |
|
|
OGI
3132
Organigram Holdings
OGI
$136M
| $304K | ﹤0.01% |
232,330
+13,203
| +6% | +$16.2K |
|
3133
Traeger
COOK
$171M
| $304K | ﹤0.01% |
2,225
+255
| +13% | +$32.9K |
|
|
LENZ
3134
LENZ Therapeutics
LENZ
$181M
| $303K | ﹤0.01% |
16,499
+1,918
| +13% | +$31.7K |
|
3135
Natural Health Trends
NHTC
$14.4M
| $300K | ﹤0.01% |
51,377
+1,823
| +4% | +$10K |
|
3136
AC Immune
ACIU
$241M
| $299K | ﹤0.01% |
59,752
| – | – |
|
3137
Gray Media Inc
GTN.A
$699M
| $295K | ﹤0.01% |
34,467
| – | – |
|
|
GRTS
3138
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $291K | ﹤0.01% |
142,730
-10,370
| -7% | -$18.9K |
|
3139
ImmuCell
ICCC
$100M
| $290K | ﹤0.01% |
57,451
-143
| -0.2% | -$698 |
|
3140
XBiotech
XBIT
$68.3M
| $290K | ﹤0.01% |
72,475
| – | – |
|
3141
Adicet Bio
ACET
$84.7M
| $290K | ﹤0.01% |
9,588
-469
| -5% | -$10.2K |
|
3142
Zevra Therapeutics
ZVRA
$570M
| $286K | ﹤0.01% |
43,605
-10,285
| -19% | -$48.1K |
|
|
SWKH
3143
DELISTED
SWK Holdings
SWKH
| $284K | ﹤0.01% |
20,466
| – | – |
|
3144
Atea Pharmaceuticals
AVIR
$379M
| $282K | ﹤0.01% |
92,351
| – | – |
|
3145
Absci
ABSI
$1.29B
| $279K | ﹤0.01% |
66,533
+36,218
| +119% | +$67.2K |
|
3146
Air T
AIRT
$75.4M
| $273K | ﹤0.01% |
16,569
-54
| -0.3% | -$1.09K |
|
3147
First Guaranty Bancshares
FGBI
$158M
| $272K | ﹤0.01% |
24,492
| – | – |
|
|
INZY
3148
DELISTED
Inozyme Pharma
INZY
| $272K | ﹤0.01% |
63,685
+4,244
| +7% | +$15.1K |
|
3149
CVD Equipment Corp
CVV
$45.2M
| $272K | ﹤0.01% |
61,294
| – | – |
|
3150
ThredUp
TDUP
$757M
| $271K | ﹤0.01% |
120,233
+81,368
| +209% | +$211K |
|
Similar funds
Dimensional Fund Advisors's Q4 2023 Portfolio in Review
As of Q4 2023, Dimensional Fund Advisors held 3,516 positions worth $342B, up 12% from $305B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Trading was light in Q4 2023: portfolio turnover was 4.3%. Dimensional Fund Advisors opened 49 new positions and exited 103, leaving the 3,516-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 17% a quarter earlier, followed by Financials and Industrials.
- Dimensional Fund Advisors's largest Q4 2023 buy was Veralto: 961,231 shares worth $79.1M.
- Dimensional Fund Advisors added most to NVIDIA in Q4 2023, an estimated $900M increase.
- Dimensional Fund Advisors's biggest Q4 2023 reduction was Meta Platforms (Facebook), cutting an estimated $430M.
- Dimensional Fund Advisors fully exited Activision Blizzard in Q4 2023, selling an estimated $305M.
- Dimensional Fund Advisors's ten largest holdings make up 12% of its $342B portfolio in Q4 2023.
- Dimensional Fund Advisors opened 49 new positions and closed 103 in Q4 2023.
- Dimensional Fund Advisors's portfolio value rose 12% quarter-over-quarter to $342B.
Based on Dimensional Fund Advisors's 13F filing for Q4 2023, filed 7 Feb 2024.